D-二聚体检测市场 - 全球产业规模、份额、趋势、机会及预测（按产品、测试类型、方法、应用、最终用途、地区和竞争格局划分，2021-2031年）

全球 D-二聚体检测市场预计将从 2025 年的 20.2 亿美元成长到 2031 年的 26.7 亿美元，复合年增长率为 4.76%。

这些检测方法透过定量或定性检测血液中的纤维蛋白降解物来发挥作用，这些产物是排除肺动脉栓塞、深层静脉栓塞症和弥散性血管内凝血等血栓事件的重要标记。市场扩张的主要驱动因素是全球凝血静脉血栓栓塞症。此外，急诊室也越来越依赖这些检测方法作为快速排除诊断手段，以简化患者就诊流程并最大限度地减少不必要的住院治疗。

然而，该检测面临一个重大挑战：特异性低。与血栓症形成无关的因素（例如恶性肿瘤、发炎、怀孕）会导致假阳性结果，因此需要昂贵的影像检查才能确诊。国际血栓与止血学会（ISSH）在2024年强调了这些疾病的严重性，指出血栓症形成占全球死亡人数的四分之一。虽然这项死亡率凸显了有效筛检的必要性，但D-二聚体检测固有的特异性限制仍然阻碍了其效率，并限制了效用。

市场驱动因素

深层静脉栓塞症(DVT) 和静脉血栓栓塞症(VTE) 的日益普及是全球 D-二聚体检测市场的主要驱动因素。由于这些疾病的症状特异性，D-二聚体检测已成为低危险群至中危险群患者排除血栓栓塞事件的标准初步筛检方法，有效减少了对昂贵影像检查的依赖。大量患者需要紧急诊断评估，凸显了应对此负担的临床需求。根据美国疾病管制与预防中心 (CDC) 2024 年 5 月发布的图表，静脉血栓栓塞症每年影响约 90 万美国人。如此高的发病率推动了对自动化平台和高灵敏度试剂的持续需求，以支持快速的临床决策。

同时，心血管疾病（CVD）发病率的上升显着推动了对止血检测的需求。 D-二聚体的应用范围已从排除性诊断扩展到作为中风、主动脉剥离和心臟衰竭等疾病风险分层的预后标记物，迫使医疗机构加强其诊断能力。美国心臟协会（AHA）于2024年1月报告称，2021年全球约有1991万人死于心血管疾病。为顺应此趋势，九龙港务集团宣布其2024年北美销售额将成长5.2%，证实了心血管风险的增加正直接推动专业诊断技术的商业性发展。

市场挑战

全球D-二聚体检测市场面临的主要限制因素是该检测本身特异性不足，这常常导致假阳性结果。由于非血栓性生理状况，例如发炎、恶性肿瘤和妊娠，也会导致D-二聚体水平升高，因此仅凭阳性结果并不能确诊血栓症形成。这项限制迫使医疗机构进行昂贵且耗费资源的影像检查（例如，肺动脉CT血管血管造影术）以排除肺动脉栓塞等疾病。因此，这些辅助检查带来的经济和营运负担降低了单独进行D-二聚体检测的成本效益，使其功能仅限于排除性诊断，而非确诊。

这种低效性造成了临床工作流程中的重大瓶颈，尤其考虑到需要评估的症状患者数量庞大。根据美国心臟协会2024年报告，美国所有静脉血栓栓塞症的估计发生率为每10万人年264.6例。鑑于血栓性疾病的高发生率，D-二聚体检测无法准确区分真阳性和假阳性，这给医疗保健系统带来了不必要的成本，并直接抑制了市场潜在的临床应用扩张。

市场趋势

新一代就地检验设备的普及正在从根本上改变市场格局，将诊断从集中式检查室转移到分散式环境。这项转变的驱动力在于携带式多功能检测平台的广泛应用，这些平台使临床医生能够在基层医疗医疗机构和患者床边进行检查室级的D-二聚体检测。这种能力对于快速分诊和即时治疗至关重要，尤其是在基础设施有限的偏远地区。罗氏于2024年7月以约2.95亿美元收购LumiraDx诊断平台，正是此产业变革的典型例证。此举凸显了微流体技术在将关键血液凝固检验整合到小型装置方面的商业性价值。

同时，机器学习和人工智慧演算法的融合正在革新D-二聚体检测的临床应用，透过先进的预测模型克服其固有的特异性限制。这些演算法结合其他生理指标分析D-二聚体数据，建构稳健的风险分层工具，显着降低假阳性率，并避免不必要的影像检查。美国血液学会于2024年12月发布的一份报告特别强调了这种方法的有效性，该报告指出，一种将D-二聚体检测结果与人工智慧分析的心电图相结合的新演算法，在预测肺动脉栓塞方面实现了0.93的曲线下面积（AUC）。随着排除演算法的不断完善，这些数位化进步正将D-二聚体检测从简单的排除性诊断工具提升为精准、自动化临床决策支援系统的重要组成部分。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球D-二聚体检测市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（分析设备、试剂和耗材）
  • 依检测类型（临床检测、就地检验）
  • 透过以下方法（酵素免疫分析法（ELISA）、乳胶增强免疫比浊法、萤光免疫分析等）
  • 依应用领域（深层静脉栓塞症、肺动脉栓塞、弥散性血管内凝血等）
  • 依最终用途（医院、学术/研究机构、诊断中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美D-二聚体检测市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲D-二聚体检测市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区D-二聚体检测市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲D-二聚体检测市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美D-二聚体检测市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球D-二聚体检测市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Abbott Laboratories, Inc.
• bioMerieux SA,
• Werfen, SA
• HORIBA, Ltd.
• QuidelOrtho Corporation
• Diazyme Laboratories, Inc.
• BioMedica Diagnostics Inc.
• Sekisui Diagnostics, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global D-dimer Testing Market is projected to expand from a valuation of USD 2.02 Billion in 2025 to reach USD 2.67 Billion by 2031, progressing at a CAGR of 4.76%. These tests function by detecting fibrin degradation products quantitatively or qualitatively in the blood, acting as a crucial exclusion marker for thrombotic events like pulmonary embolism, deep vein thrombosis, and disseminated intravascular coagulation. Market expansion is chiefly driven by the rising global incidence of coagulation disorders and a growing elderly population prone to venous thromboembolism. Additionally, emergency departments increasingly rely on these assays for rapid exclusion diagnostics to streamline patient flow and minimize unwarranted hospital admissions.

However, the market confronts a major obstacle regarding the test's low specificity, as factors unrelated to thrombosis-such as malignancy, inflammation, or pregnancy-can trigger false-positive outcomes, necessitating costly confirmatory imaging. The International Society on Thrombosis and Haemostasis highlighted the severity of these conditions in 2024, noting that thrombosis underlies one in four deaths globally. While this mortality rate emphasizes the critical need for effective screening, the inherent specificity limitations of D-dimer assays continue to hinder their efficiency and restrict their standalone utility in clinical settings.

Market Driver

The escalating prevalence of Deep Vein Thrombosis (DVT) and Venous Thromboembolism (VTE) serves as the primary engine for the global D-dimer testing market. Since these conditions manifest with non-specific symptoms, D-dimer assays have become the standard initial screening method to exclude thromboembolic events in low-to-moderate risk patients, effectively reducing reliance on expensive imaging techniques. The clinical necessity to manage this burden is underscored by the high volume of patients requiring urgent diagnostic assessment; according to a May 2024 infographic by the Centers for Disease Control and Prevention, venous thromboembolism impacts nearly 900,000 Americans annually. This high incidence rate drives the continuous demand for automated platforms and high-sensitivity reagents to support rapid clinical decision-making.

Concurrently, the rising rates of cardiovascular diseases (CVD) are significantly increasing the demand for hemostasis testing. D-dimer applications have expanded beyond exclusion to serve as prognostic markers for risk stratification in stroke, aortic dissection, and heart failure cases, prompting healthcare facilities to enhance their diagnostic capabilities. The American Heart Association reported in January 2024 that cardiovascular disease was responsible for roughly 19.91 million deaths globally in 2021. Reflecting this trend, Werfen reported a 5.2% growth in North American sales revenue in 2024, confirming that increasing cardiovascular risks are directly fueling the commercial momentum for specialized diagnostic technologies.

Market Challenge

A major constraint facing the Global D-dimer Testing Market is the assay's inherent lack of specificity, which often leads to false-positive results. Since elevated D-dimer levels can be triggered by non-thrombotic physiological conditions like inflammation, malignancy, or pregnancy, a positive reading cannot definitively diagnose thrombosis. This limitation forces medical providers to employ costly and resource-heavy confirmatory imaging, such as Computed Tomography Pulmonary Angiography, to exclude conditions like pulmonary embolism. Consequently, the financial and operational strain of these secondary procedures diminishes the standalone cost-effectiveness of D-dimer testing, confining it to an exclusionary function rather than a definitive diagnostic role.

This inefficiency generates significant bottlenecks in clinical workflows, particularly considering the high volume of patients presenting with symptoms needing evaluation. As reported by the American Heart Association in 2024, the estimated incidence rate for all venous thromboembolism in the United States was 264.6 per 100,000 person-years. Given such a high incidence of thrombotic conditions, the failure of D-dimer assays to accurately differentiate between actual cases and false alarms imposes avoidable costs on healthcare systems, directly impeding the market's potential for more extensive clinical dependence.

Market Trends

The proliferation of Next-Generation Point-of-Care Testing Devices is fundamentally transforming the market by moving diagnostics from centralized laboratories to decentralized environments. This shift is driven by the broad uptake of portable, multi-assay platforms that enable clinicians to conduct laboratory-grade D-dimer testing in primary care clinics or at the patient's bedside. Such capabilities are essential for speeding up triage and enabling immediate treatment, especially in remote regions with limited infrastructure. This industry-wide transition was validated in July 2024 when Roche acquired LumiraDx's diagnostics platform for roughly $295 million, a move that underscores the commercial value of microfluidic technologies integrating critical coagulation assays into compact devices.

Simultaneously, the integration of Machine Learning and Artificial Intelligence algorithms is revolutionizing the clinical application of D-dimer assays by mitigating their inherent specificity constraints through advanced predictive modeling. These algorithms analyze D-dimer data alongside other physiological metrics to build robust risk stratification tools that notably lower false-positive rates and reduce unnecessary imaging. The effectiveness of this method was highlighted in a December 2024 report by the American Society of Hematology, which noted that a new algorithm combining D-dimer results with AI-analyzed electrocardiograms achieved an area under the curve (AUC) of 0.93 for predicting pulmonary embolisms. By refining exclusion algorithms, these digital advancements are elevating D-dimer tests from simple rule-out tools to integral parts of precise, automated clinical decision support systems.

Key Market Players

• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Siemens Healthineers AG
• Abbott Laboratories, Inc.
• bioMerieux S.A.,
• Werfen, S.A.
• HORIBA, Ltd.
• QuidelOrtho Corporation
• Diazyme Laboratories, Inc.
• BioMedica Diagnostics Inc.
• Sekisui Diagnostics, LLC

Report Scope

In this report, the Global D-dimer Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

D-dimer Testing Market, By Product

• Analyzers
• Reagents & Consumables

D-dimer Testing Market, By Test Type

• Clinical Laboratory Tests
• Point-of-Care Tests

D-dimer Testing Market, By Method

• Enzyme-linked Immunosorbent Assay {ELISA}
• Latex-enhanced Immunoturbidimetric Assays
• Fluorescence Immunoassays
• Others

D-dimer Testing Market, By Application

• Deep Vein Thrombosis
• Pulmonary Embolism
• Disseminated Intravascular Coagulation
• Others

D-dimer Testing Market, By End Use

• Hospitals
• Academic & Research Institutes
• Diagnostic Centers
• Others

D-dimer Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global D-dimer Testing Market.

Available Customizations:

Global D-dimer Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global D-dimer Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Analyzers, Reagents & Consumables)
  • 5.2.2. By Test Type (Clinical Laboratory Tests, Point-of-Care Tests)
  • 5.2.3. By Method (Enzyme-linked Immunosorbent Assay {ELISA}, Latex-enhanced Immunoturbidimetric Assays, Fluorescence Immunoassays, Others)
  • 5.2.4. By Application (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, Others)
  • 5.2.5. By End Use (Hospitals, Academic & Research Institutes, Diagnostic Centers, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America D-dimer Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Test Type
  • 6.2.3. By Method
  • 6.2.4. By Application
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States D-dimer Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Method
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada D-dimer Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Method
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico D-dimer Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Method
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End Use

7. Europe D-dimer Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Test Type
  • 7.2.3. By Method
  • 7.2.4. By Application
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany D-dimer Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Method
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End Use
  • 7.3.2. France D-dimer Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Method
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom D-dimer Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Method
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy D-dimer Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Method
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain D-dimer Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Method
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End Use

8. Asia Pacific D-dimer Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Test Type
  • 8.2.3. By Method
  • 8.2.4. By Application
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China D-dimer Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Method
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End Use
  • 8.3.2. India D-dimer Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Method
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan D-dimer Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Method
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea D-dimer Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Method
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia D-dimer Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Method
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End Use

9. Middle East & Africa D-dimer Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Test Type
  • 9.2.3. By Method
  • 9.2.4. By Application
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia D-dimer Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Method
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE D-dimer Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Method
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa D-dimer Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Method
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End Use

10. South America D-dimer Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Test Type
  • 10.2.3. By Method
  • 10.2.4. By Application
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil D-dimer Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Method
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia D-dimer Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Method
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina D-dimer Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Method
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global D-dimer Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd
• 15.3. Siemens Healthineers AG
• 15.4. Abbott Laboratories, Inc.
• 15.5. bioMerieux S.A.,
• 15.6. Werfen, S.A.
• 15.7. HORIBA, Ltd.
• 15.8. QuidelOrtho Corporation
• 15.9. Diazyme Laboratories, Inc.
• 15.10. BioMedica Diagnostics Inc.
• 15.11. Sekisui Diagnostics, LLC

16. Strategic Recommendations

17. About Us & Disclaimer